by MM360 Staff | Jan 29, 2026 | Publications
Front Immunol. 2026 Jan 12;16:1722579. doi: 10.3389/fimmu.2025.1722579. eCollection 2025. ABSTRACT Bispecific antibodies are a novel class of immunotherapies that have demonstrated high response rates in heavily pretreated patients with multiple myeloma. However,...
by MM360 Staff | Jan 23, 2026 | Publications
Front Immunol. 2026 Jan 6;16:1744165. doi: 10.3389/fimmu.2025.1744165. eCollection 2025. ABSTRACT BACKGROUND: The efficacy of CD38 monoclonal antibody (mAb)-based quadruplet regimens versus triplet regimens in newly diagnosed multiple myeloma (NDMM) patients with...
by MM360 Staff | Jan 23, 2026 | Publications
EClinicalMedicine. 2026 Jan 8;91:103750. doi: 10.1016/j.eclinm.2025.103750. eCollection 2026 Jan. ABSTRACT BACKGROUND: Diagnostic advancements and classification updates appear to have reshaped the natural history of smoldering multiple myeloma (SMM), though this...
by MM360 Staff | Jan 23, 2026 | Publications
Front Oncol. 2026 Jan 6;15:1729177. doi: 10.3389/fonc.2025.1729177. eCollection 2025. ABSTRACT Daratumumab, a CD38-targeting monoclonal antibody, is a key component of therapy for both newly diagnosed and relapsed or refractory multiple myeloma. By depleting...
by MM360 Staff | Jan 23, 2026 | Publications
Front Oncol. 2026 Jan 6;15:1747354. doi: 10.3389/fonc.2025.1747354. eCollection 2025. ABSTRACT OBJECTIVE: To conduct a comprehensive comparison of the efficacy, safety, and cost-effectiveness of denosumab versus zoledronic acid in patients with bone metastases from...
by MM360 Staff | Jan 10, 2026 | Publications
Hematology. 2026 Dec;31(1):2613505. doi: 10.1080/16078454.2026.2613505. Epub 2026 Jan 8. ABSTRACT Objectives: The introduction of novel therapies has markedly improved the prognosis of multiple myeloma (MM), yet relapse remains common. For patients with relapsed or...
